These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34217136)

  • 1. Triple-negative breast cancer on contrast-enhanced MRI and synthetic MRI: A comparison with non-triple-negative breast carcinoma.
    Matsuda M; Tsuda T; Ebihara R; Toshimori W; Okada K; Takeda S; Okumura A; Shiraishi Y; Suekuni H; Kamei Y; Kurata M; Kitazawa R; Mochizuki T; Kido T
    Eur J Radiol; 2021 Sep; 142():109838. PubMed ID: 34217136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multiparametric approach to predict triple-negative breast cancer including parameters derived from ultrafast dynamic contrast-enhanced MRI.
    Ohashi A; Kataoka M; Iima M; Honda M; Ota R; Urushibata Y; Dominik Nickel M; Toi M; Zackrisson S; Nakamoto Y
    Eur Radiol; 2023 Nov; 33(11):8132-8141. PubMed ID: 37286791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of synthetic MRI in predicting pathological complete response of various breast cancer subtypes prior to neoadjuvant chemotherapy.
    Matsuda M; Fukuyama N; Matsuda T; Kikuchi S; Shiraishi Y; Takimoto Y; Kamei Y; Kurata M; Kitazawa R; Kido T
    Clin Radiol; 2022 Nov; 77(11):855-863. PubMed ID: 36055826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of synthetic MRI in predicting the Ki-67 status of oestrogen receptor-positive breast cancer: a feasibility study.
    Matsuda M; Kido T; Tsuda T; Okada K; Shiraishi Y; Suekuni H; Kamei Y; Kitazawa R; Mochizuki T
    Clin Radiol; 2020 May; 75(5):398.e1-398.e8. PubMed ID: 32019671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.
    Youk JH; Son EJ; Chung J; Kim JA; Kim EK
    Eur Radiol; 2012 Aug; 22(8):1724-34. PubMed ID: 22527371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of triple-negative breast cancer and androgen receptor expression based on histogram and texture analysis of dynamic contrast-enhanced MRI.
    Xu WJ; Zheng BJ; Lu J; Liu SY; Li HL
    BMC Med Imaging; 2023 Jun; 23(1):70. PubMed ID: 37264313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological and Semiquantitative Kinetic Analysis on Dynamic Contrast Enhanced MRI in Triple Negative Breast Cancer Patients.
    Gigli S; Amabile MI; David E; De Luca A; Grippo C; Manganaro L; Monti M; Ballesio L
    Acad Radiol; 2019 May; 26(5):620-625. PubMed ID: 30145205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment synthetic MRI features for triple-negative breast cancer.
    Zhang Q; Zhao Y; Nie J; Long Q; Wang X; Wang X; Gong G; Liao L; Yi X; Chen BT
    Clin Radiol; 2024 Feb; 79(2):e219-e226. PubMed ID: 37935611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiomics Analysis Based on Automatic Image Segmentation of DCE-MRI for Predicting Triple-Negative and Nontriple-Negative Breast Cancer.
    Ma M; Gan L; Jiang Y; Qin N; Li C; Zhang Y; Wang X
    Comput Math Methods Med; 2021; 2021():2140465. PubMed ID: 34422088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do Habitat MRI and Fractal Analysis Help Distinguish Triple-Negative Breast Cancer From Non-Triple-Negative Breast Carcinoma.
    Xu R; Yu D; Luo P; Li X; Jiang L; Chang S; Li G
    Can Assoc Radiol J; 2024 Aug; 75(3):584-592. PubMed ID: 38389194
    [No Abstract]   [Full Text] [Related]  

  • 11. Enhanced Masses on Contrast-Enhanced Breast: Differentiation Using a Combination of Dynamic Contrast-Enhanced MRI and Quantitative Evaluation with Synthetic MRI.
    Matsuda M; Tsuda T; Ebihara R; Toshimori W; Takeda S; Okada K; Nakasuka K; Shiraishi Y; Suekuni H; Kamei Y; Kurata M; Kitazawa R; Mochizuki T; Kido T
    J Magn Reson Imaging; 2021 Feb; 53(2):381-391. PubMed ID: 32914921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer.
    Musall BC; Abdelhafez AH; Adrada BE; Candelaria RP; Mohamed RMM; Boge M; Le-Petross H; Arribas E; Lane DL; Spak DA; Leung JWT; Hwang KP; Son JB; Elshafeey NA; Mahmoud HS; Wei P; Sun J; Zhang S; White JB; Ravenberg EE; Litton JK; Damodaran S; Thompson AM; Moulder SL; Yang WT; Pagel MD; Rauch GM; Ma J
    J Magn Reson Imaging; 2021 Jul; 54(1):251-260. PubMed ID: 33586845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).
    Abdelhafez AH; Musall BC; Adrada BE; Hess K; Son JB; Hwang KP; Candelaria RP; Santiago L; Whitman GJ; Le-Petross HT; Moseley TW; Arribas E; Lane DL; Scoggins ME; Leung JWT; Mahmoud HS; White JB; Ravenberg EE; Litton JK; Valero V; Wei P; Thompson AM; Moulder SL; Pagel MD; Ma J; Yang WT; Rauch GM
    Breast Cancer Res Treat; 2021 Jan; 185(1):1-12. PubMed ID: 32920733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Test-Retest Performance of a 1-Hour Multiparametric MR Image Acquisition Pipeline With Orthotopic Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts.
    Ge X; Quirk JD; Engelbach JA; Bretthorst GL; Li S; Shoghi KI; Garbow JR; Ackerman JJH
    Tomography; 2019 Sep; 5(3):320-331. PubMed ID: 31572793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic MRI with quantitative mappings for identifying receptor status, proliferation rate, and molecular subtypes of breast cancer.
    Gao W; Yang Q; Li X; Chen X; Wei X; Diao Y; Zhang Y; Chen C; Guo B; Wang Y; Lei Z; Zhang S
    Eur J Radiol; 2022 Mar; 148():110168. PubMed ID: 35078137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved discrimination of molecular subtypes in invasive breast cancer: Comparison of multiple quantitative parameters from breast MRI.
    Du S; Gao S; Zhang L; Yang X; Qi X; Li S
    Magn Reson Imaging; 2021 Apr; 77():148-158. PubMed ID: 33309922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of synthetic MRI in differential diagnosis of benign and malignant breast lesions].
    Che SN; Li J; Xue M; Song Y; Zhao LY; Guo N; Tian Y; Xie LZ; Zhao XM; Zhou CW
    Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):872-877. PubMed ID: 34407594
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictive value of triple negative breast cancer based on DCE-MRI multi-phase full-volume ROI clinical radiomics model.
    Qi X; Wang W; Pan S; Liu G; Xia L; Duan S; He Y
    Acta Radiol; 2024 Feb; 65(2):173-184. PubMed ID: 38017694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Added value of histogram analysis of apparent diffusion coefficient maps for differentiating triple-negative breast cancer from other subtypes of breast cancer on standard MRI.
    Liu HL; Zong M; Wei H; Wang C; Lou JJ; Wang SQ; Zou QG; Jiang YN
    Cancer Manag Res; 2019; 11():8239-8247. PubMed ID: 31564982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of breast MRI in evaluation of triple-negative breast cancer and fibroadenoma of less than 3 cm.
    Wei Z; Chen X; Yang Y; Yang L; Ma X
    Transl Cancer Res; 2024 Aug; 13(8):4042-4051. PubMed ID: 39262467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.